Study of AZD2389 safety, tolerability, and pharmacodynamics in adults with steatotic liver disease and advanced fibrosis

Trial Identifier: D7930C00008
Sponsor: AstraZeneca
Start Date: May 2026
Primary Completion Date: July 2027
Study Completion Date: July 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AZ Chandler, AZ, US, 85224
US, FL Jupiter, FL, US, 33458
US, FL Miami, FL, US, 33122
US, FL Port Orange, FL, US, 32127
US, MO Kansas City, MO, US, 64131
US, MO Saint Louis, MO, US, 63123
US, NC Morehead City, NC, US, 28557
US, NC Raleigh, NC, US, 27607
US, NV Las Vegas, NV, US, 89106
US, OH Westlake, OH, US, 44145
US, OK Yukon, OK, US, 73099
US, TN Clarksville, TN, US, 37040
US, TX Austin, TX, US, 78757
US, TX Denison, TX, US, 75020
US, TX Georgetown, TX, US, 78626
US, TX Houston, TX, US, 77079
US, TX Houston, TX, US, 77004
US, TX San Antonio, TX, US, 78215
US, TX San Antonio, TX, US, 78222